Aligos Therapeutics Reports Significant Q1 Loss, Announces $25M Upfront Licensing Deal, and Reiterates Going Concern Warning

summarizeSummary

Aligos Therapeutics reported a significant Q1 2026 net loss and reiterated its 'going concern' warning, projecting a cash runway only into Q4 2026, despite securing a new licensing deal with Amoytop Biotech for $25 million upfront and up to $420 million in milestones.

check_boxKey Events

• Significant Quarterly Net Loss

  The company reported a net loss of $23.04 million for the first quarter of 2026, a substantial decline from a net income of $43.088 million in the prior-year quarter (which included a large non-cash gain from warrant revaluation).

• Persistent Going Concern Warning

  Aligos Therapeutics continues to raise 'substantial doubt' about its ability to continue as a going concern, projecting its cash runway only into the fourth quarter of 2026, even after accounting for a new $25 million upfront payment.

• New Licensing Deal with Amoytop Biotech

  In a subsequent event, the company entered into an exclusive license agreement with Amoytop Biotech in April 2026 for pevifoscorvir sodium in Greater China, receiving a $25 million upfront payment and eligible for up to $420 million in clinical, regulatory, and sales milestones.

• Increased R&D Expenses

  Research and development expenses increased by $8.9 million to $23.352 million in Q1 2026, primarily due to higher clinical study costs for the Phase 2 B-SUPREME trial of pevifoscorvir sodium.

auto_awesomeAnalysis

Aligos Therapeutics reported a net loss of $23.04 million for Q1 2026, a substantial increase from a net income of $43.088 million in Q1 2025 (which included a large non-cash warrant revaluation gain). The company's operating loss also increased significantly. Despite a new exclusive license agreement with Amoytop Biotech in April 2026, which includes a $25 million upfront payment and up to $420 million in potential milestones, the company explicitly states that its cash, cash equivalents, and short-term investments of $54.9 million (as of March 31, 2026) will only fund operations into Q4 2026. This continued 'going concern' warning, even with the substantial new financing, underscores the company's high cash burn rate and ongoing need for additional capital. The Phase 2 B-SUPREME study for pevifoscorvir sodium saw an interim analysis recommend an increased sample size for one cohort, a yellow flag, though futility criteria were not met.